Genetic markers for engraftment of human cardiac ventricular progenitor cells

• US 10,612,094 B2
• Filed: 02/15/2017
• Issued: 04/07/2020
• Est. Priority Date: 02/19/2016
• Status: Active Grant

• Current Assignee: Procella Therapeutics AB
• Original Assignee: Procella Therapeutics AB
• Inventors: Leung, Chuen Yan, Clarke, Jonathan, Xu, Jiejia, Santoro, Federica, Sahara, Makoto, Chien, Kenneth R.
• Primary Examiner(s): Long, Scott
• Application Number:
  US15/433,713
• Publication Number:
  US 20170240964A1
• Time in Patent Office: 1,147 Days
• CPC Class Codes: A61K 35/34 Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2501/42 Notch; Delta; Jagged; Serrate
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention provides genetic markers for identifying engraftable human cardiac ventricular progenitor cells. The engraftment markers of the invention include angiogenic markers and extracellular matrix markers. Human ventricular progenitor cells expressing these markers are capable of forming ventricular tissue in vivo that is vascularized and supported by an extracellular matrix. Methods of engrafting human cardiac ventricular progenitor cells by transplanting into a subject progenitor cells that express the engraftment markers are also provided.

Claims

1. A method of transplanting engraftable human ventricular progenitor cells (HVPs), the method comprising:

culturing human cells containing cardiac progenitor cells (CPCs) under conditions causing differentiation into human ventricular progenitor cells (HVPs) by subjecting human pluripotent stem cells to activation of Wnt/β

-catenin signaling on day 0, followed by inhibition of Wnt/β

-catenin signaling from day 3 to day 5 to thereby obtain a culture of day 5-7 CPCs comprising day 5-7 LIFR+ Islet1+HVPs;

detecting expression on the HVPs of at least one surface marker selected from the group consisting of JAG1, FZD4, FGFR3 and/or TNFSF9 on the day 5-7 HVPs;

detecting expression in the day 5-7 HVPs of at least one engraftment markers;

isolating day 5-7 HVPs that co-express the at least one surface marker and the at least one engraftment markers to thereby isolate engraftable day 5-7 HVPs; and

transplanting the engraftable day 5-7 HVPs into a subject such that the engraftable day 5-7 HVPs form a vascularized, electrically responsive ventricular muscle patch that secretes an extracellular matrix.

2. The method of claim 1, wherein five or more positive angiogenic markers are detected.

3. The method of claim 1, wherein ten or more positive angiogenic markers are detected.

4. The method of claim 1, wherein five or more positive extracellular matrix markers are detected.

5. The method of claim 1, wherein ten or more positive extracellular matrix markers are detected.

6. The method of claim 1, wherein detecting expression in the HVPs of at least one engraftment marker comprises detecting expression of at least one positive angiogenic marker and at least one positive extracellular matrix marker.

7. The method of claim 6, wherein the at least one positive angiogenic marker is selected from the group consisting of:

FGF10, PRKD1, CCBE1, PDGFRA, EPHB2, GATA2, NTRK1, PTGIS, BMPER, BMP4, C1GALT1, MEIS1, TBX1, PKNOX1, ID1, TCF21, HEY1, HOXB3, HGF, IL6, GHRL, IHH, SRPK2, GATA6, HAND1, AMOT, NRP2, PTEN, SEMA3E, APOLD1, SETD2, DAB2IP, KDR, PGF, EMP2, TAL1, ACVR1, HIPK2, CSPG4, TNFAIP3, NRP1, NFATC4, CDC42, ANGPTL4, BCAS3, HIPK1, NRXN3, FZD5 and HHEX.

8. The method of claim 7, wherein the at least one positive angiogenic marker is selected from the group consisting of:

FGF10, PRKD1, CCBE1, PDGFRA, EPHB2, GATA2, NTRK1, PTGIS, BMPER, BMP4, C1GALT1, MEIS1, TBX1, PKNOX1, ID1, TCF21 and HEY1.

9. The method of claim 7, wherein the at least positive angiogenic marker is selected from the group consisting of:

FGF10, PRKD1, CCBE1, PDGFRA, EPHB2, GATA2 and NTRK1.

10. The method of claim 4, wherein the at least one positive extracellular matrix marker is selected from the group consisting of:

FGF10, SMOC1, CCBE1, COL6A6, ADAMTS12, COL19A1, LAMA1, BMP4, FBLN7, FBLN2, NDNF, HTRA1, HAPLN1, EMILIN1, SPOCK3, PODNL1, IHH, ACAN, NID2, COL4A6, LAMC1, FMOD, MUC4, EMID1, HMCN1, NID1, VCAN, CILP2, SOD3, ADAMTS3, ZP3, ANGPTL4, CRTAC1, LTBP4 and FREM1.

11. The method of claim 10, wherein the at least one positive extracellular matrix marker is selected from the group consisting of:

FGF10, SMOC1, CCBE1, COL6A6, ADAMTS12, COL19A1, LAMA1, BMP4, FBLN7, FBLN2, NDNF and HTRA1.

12. The method of claim 10, wherein the at least one positive extracellular matrix marker is selected from the group consisting of:

FGF10, SMOC1 and CCBE1.

13. The method of claim 6, wherein:

the at least one positive angiogenic marker is selected from the group consisting of;

FGF10, PRKD1, CCBE1, PDGFRA, EPHB2, GATA2, NTRK1, PTGIS, BMPER, BMP4, C1GALT1, MEIS1, TBX1, PKNOX1, ID1, TCF21, HEY1, HOXB3, HGF, IL6, GHRL, IHH, SRPK2, GATA6, HAND1, AMOT, NRP2, PTEN, SEMA3E, APOLD1, SETD2, DAB2IP, KDR, PGF, EMP2, TAL1, ACVR1, HIPK2, CSPG4, TNFAIP3, NRP1, NFATC4, CDC42, ANGPTL4, BCAS3, HIPK1, NRXN3, FZD5 and HHEX; and

the at least one positive extracellular matrix marker is selected from the group consisting of;

FGF10, SMOC1, CCBE1, COL6A6, ADAMTS12, COL19A1, LAMA1, BMP4, FBLN7, FBLN2, NDNF, HTRA1, HAPLN1, EMILIN1, SPOCK3, PODNL1, IHH, ACAN, NID2, COL4A6, LAMC1, FMOD, MUC4, EMID1, HMCN1, NID1, VCAN, CILP2, SOD3, ADAMTS3, ZP3, ANGPTL4, CRTAC1, LTBP4 and FREM1.

14. The method of claim 13, wherein:

the at least one positive angiogenic marker is selected from the group consisting of;

FGF10, PRKD1, CCBE1, PDGFRA, EPHB2, GATA2, NTRK1, PTGIS, BMPER, BMP4, C1GALT1, MEIS1, TBX1, PKNOX1, ID1, TCF21 and HEY1; and

the at least one positive extracellular matrix marker is selected from the group consisting of;

FGF10, SMOC1, CCBE1, COL6A6, ADAMTS12, COL19A1, LAMA1, BMP4, FBLN7, FBLN2, NDNF and HTRA1.

15. The method of claim 13, wherein:

the at least one positive angiogenic marker is selected from the group consisting of;

FGF10, PRKD1, CCBE1, PDGFRA, EPHB2, GATA2 and NTRK1; and

the at least one positive extracellular matrix marker is selected from the group consisting of;

FGF10, SMOC1 and CCBE1.

16. The method of claim 1, wherein the at least one engraftment markers detected comprise at least one negative angiogenic marker.

17. The method of claim 1, wherein the at least one engraftment markers detected comprise at least one negative extracellular matrix marker.

18. The method of claim 1, herein detecting expression in the HVPs of at least one engraftment marker comprises detecting expression of at least one negative angiogenic marker and at least one negative extracellular matrix marker.

19. The method of claim 16, wherein the at least one negative angiogenic marker is selected from the group consisting of:

ETS1, BAX, XBP1, TDGF1, C5AR1, EPHA1, HS6ST1, SHC1, SP100, JAM3, CASP8, FLT4, SFRP2, HPSE, BAK1, GPX1, VAV3, VAV2, EGF, ADAM15 and AGGF1.

20. The method of claim 19, wherein the at least one negative angiogenic marker is selected from the group consisting of:

VAV3, VAV2, EGF, ADAM15 and AGGF1.

21. The method of claim 17, wherein the at least one negative extracellular matrix marker is selected from the group consisting of:

FKBP1A, CLU, TFP12, PLSCR1, FBLN5, VWA1, ADAMTS16, MMP25, SFRP2 and SOD1.

22. The method of claim 18, wherein:

the at least one negative angiogenic marker is selected from the group consisting of;

ETS1, BAX, XBP1, TDGF1, C5AR1, EPHA1, HS6ST1, SHC1, SP100, JAM3, CASP8, FLT4, SFRP2, HPSE, BAK1, GPX1, VAV3, VAV2, EGF, ADAM15 and AGGF1; and

the at least one negative extracellular matrix marker is selected from the group consisting of;

FKBP1A, CLU, TFP12, PLSCR1, FBLN5, VWA1, ADAMTS16, MMP25, SFRP2 and SOD1.

23. The method of claim 1, wherein detecting expression of at least one engraftment markers comprises detecting expression of mRNA encoding the at least one engraftment marker in the HVPs.

24. The method of claim 1, wherein detecting expression of at least one engraftment markers comprises detecting lack of expression of mRNA encoding the at least one engraftment marker in the HVPs.

25. A method of identifying engraftable human ventricular progenitor cells (HVPs), the method comprising:

detecting expression of three or more positive extracellular matrix markers selected from the group consisting of;

FGF10, SMOC1, CCBE1, COL6A6, ADAMTS12, COL19A1, LAMA1, BMP4, FBLN7, FBLN2, NDNF, HTRA1, HAPLN1, EMILIN1, SPOCK3, PODNL1, IHH, ACAN, NID2, COL4A6, LAMC1, FMOD, MUC4, EMID1, HMCN1, NID1, VCAN, CILP2, SOD3, ADAMTS3, ZP3, ANGPTL4, CRTAC1, LTBP4 and FREM1 in the HVPs to thereby identify engraftable HVPs, wherein;

the HVPs are obtained from a culture of day 5-7 cardiac progenitor cells (CPCs), wherein the culture of day 5-7 CPCs is obtained by subjecting human pluripotent stem cells to activation of the Wnt/β

-catenin signaling on day 0, followed by inhibition of Wnt/β

-catenin signaling from day 3 to day 5; and

wherein

the HVPs also express at least one surface marker selected from the group consisting of;

JAG1, FZD4, LIFR, FGFR3 and/or TNFSF9.

26. The method of claim 25, wherein the three or more positive extracellular matrix markers are selected from the group consisting of:

FGF10, SMOC1, CCBE1, COL6A6, ADAMTS12, COL19A1, LAMA1, BMP4, FBLN7, FBLN2, NDNF and HTRA1.

27. The method of claim 25, wherein the three or more positive extracellular matrix markers comprise FGF10, SMOC1 and CCBE1.

28. A method of identifying engraftable human ventricular progenitor cells (HVPs), the method comprising:

detecting expression of at least one positive angiogenesis marker selected from the group consisting of PRKD1, CCBE1, PDGFRA, EPHB2, GATA2, NTRK1, PTGIS, BMPER, C1GALT1, MEIS1, TBX1, PKNOX1, ID1, TCF21, HEY1, HOXB3, HGF, IL6, GHRL, IHH, SRPK2, HAND1, AMOT, NRP2, PTEN, SEMA3E, APOLD1, SETD2, DAB2IP, KDR, PGF, EMP2, TAL1, HIPK2, CSPG4, TNFAIP3, NRP1, NFATC4, CDC42, ANGPTL4, BCAS3, HIPK1, NRXN3, FZD5 and HHEX; and

/or

detecting expression of at least one positive extracellular matrix markers selected from the group consisting of SMOC1, CCBE1, COL6A6, ADAMTS12, COL19A1, LAMA1, FBLN7, FBLN2, NDNF, HTRA1, HAPLN1, EMILIN1, SPOCK3, PODNL1, IHH, ACAN, NID2, COL4A6, LAMC1, FMOD, MUC4, EMID1, HMCN1, NID1, VCAN, CILP2, SOD3, ADAMTS3, ZP3, ANGPTL4, CRTAC1, LTBP4 and FREM1

in the HVPs to thereby identify engraftable HVPs, wherein;

the HVPs are obtained from a culture of day 5-7 cardiac progenitor cells (CPCs), wherein the culture of day 5-7 CPCs is obtained by subjecting human pluripotent stem cells to activation of the Wnt/β

-catenin signaling on day 0, followed by inhibition of Wnt/β

-catenin signaling from day 3 to day 5; and

wherein

the HVPs also express at least one surface marker selected from the group consisting of;

JAG1, FZD4, LIFR and/or TNFSF9.

29. The method of claim 28, which comprises detecting expression of at least one positive angiogenic marker and at least one positive extracellular matrix marker in the HVPs.

30. The method of claim 28, wherein the at least one positive angiogenic marker is selected from the group consisting of:

PRKD1, CCBE1, PDGFRA, EPHB2, GATA2, NTRK1, PTGIS, BMPER, C1GALT1, MEIS1, TBX1, PKNOX1, ID1, TCF21 and HEY1.

31. The method of claim 28, wherein the at least positive angiogenic marker is selected from the group consisting of:

PRKD1, CCBE1, PDGFRA, EPHB2, GATA2 and NTRK1.

32. The method of claim 28, wherein the at least one positive extracellular matrix marker is selected from the group consisting of:

SMOC1, CCBE1, COL6A6, ADAMTS12, COL19A1, LAMA1, FBLN7, FBLN2, NDNF and HTRA1.

33. The method of claim 28, wherein the at least one positive extracellular matrix marker is selected from the group consisting of:

SMOC1 and CCBE1.

34. A method of identifying engraftable human ventricular progenitor cells (HVPs), the method comprising:

detecting expression of ten or more positive angiogenic markers in the HVPs to thereby identify engraftable HVPs, wherein;

the HVPs are obtained from a culture of day 5-7 cardiac progenitor cells (CPCs), wherein the culture of day 5-7 CPCs is obtained by subjecting human pluripotent stem cells to activation of the Wnt/β

-catenin signaling on day 0, followed by inhibition of Wnt/β

-catenin signaling from day 3 to day 5; and

wherein

the HVPs also express at least one surface marker selected from the group consisting of;

JAG1, FZD4, LIFR, FGFR3 and/or TNFSF9.

35. The method of claim 34, wherein the ten or more positive angiogenic markers are selected from the group consisting of:

FGF10, PRKD1, CCBE1, PDGFRA, EPHB2, GATA2, NTRK1, PTGIS, BMPER, BMP4, C1GALT1, MEIS1, TBX1, PKNOX1, ID1, TCF21, HEY1, HOXB3, HGF, IL6, GHRL, IHH, SRPK2, GATA6, HAND1, AMOT, NRP2, PTEN, SEMA3E, APOLD1, SETD2, DAB2IP, KDR, PGF, EMP2, TAL1, ACVR1, HIPK2, CSPG4, TNFAIP3, NRP1, NFATC4, CDC42, ANGPTL4, BCAS3, HIPK1, NRXN3, FZD5 and HHEX.

36. A method of identifying engraftable human ventricular progenitor cells (HVPs), the method comprising:

detecting expression of five or more positive extracellular matrix markers in the HVPs to thereby identify engraftable HVPs, wherein;

the HVPs are obtained from a culture of day 5-7 cardiac progenitor cells (CPCs), wherein the culture of day 5-7 CPCs is obtained by subjecting human pluripotent stem cells to activation of the Wnt/β

-catenin signaling on day 0, followed by inhibition of Wnt/β

-catenin signaling from day 3 to day 5; and

wherein

the HVPs also express at least one surface marker selected from the group consisting of;

JAG1, FZD4, LIFR, FGFR3 and/or TNFSF9.

37. The method of claim 36, wherein ten or more positive extracellular matrix markers are detected.

38. The method of claim 36, wherein the five or more positive extracellular matrix marker are selected from the group consisting of:

FGF10, SMOC1, CCBE1, COL6A6, ADAMTS12, COL19A1, LAMA1, BMP4, FBLN7, FBLN2, NDNF, HTRA1, HAPLN1, EMILIN1, SPOCK3, PODNL1, IHH, ACAN, NID2, COL4A6, LAMC1, FMOD, MUC4, EMID1, HMCN1, NID1, VCAN, CILP2, SOD3, ADAMTS3, ZP3, ANGPTL4, CRTAC1, LTBP4 and FREM1.